Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial

INTRODUCTION: Malignant peritoneal mesothelioma (MPM) is an uncommon but aggressive neoplasm and has a strong association with asbestos exposure. MPM has low survival rates of approximately 1 year even after (palliative) surgery and/or systemic chemotherapy. Recent advances in treatment strategies f...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boer, Nadine L, van Kooten, Job P, Burger, Jacobus W A, Verhoef, Cornelis, Aerts, Joachim G J V, Madsen, Eva V E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530331/
https://www.ncbi.nlm.nih.gov/pubmed/31092657
http://dx.doi.org/10.1136/bmjopen-2018-026779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530331/
https://www.ncbi.nlm.nih.gov/pubmed/31092657
http://dx.doi.org/10.1136/bmjopen-2018-026779

Ejemplares similares